Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Thyroid Disorders
Do you recommend low dose RAI ablation for low risk papillary thyroid cancer with lymphatic invasion alone (no angio-invasion or known nodal involvement)?
Answer from: at Community Practice
No. Unless other factors, such as grossly positive margins.
Sign In
or
Register
to read more
26899
Related Questions
For patients with Hashimoto's thyroiditis, is there a commercially available blood test for detecting abnormalities in the type 1 deiodinase enzyme in order to identify patients who would potentially benefit from T4 and T3 combination therapy?
How do you adjust levothyroxine dose for elderly individuals with decompensated heart failure on low dose levothyroxine therapy presenting with TSH >10?
Would you ever recommend radiofrequency ablation over surgery or radioiodine for a patient with an autonomously functioning thyroid nodule?
Does papillary thyroid cancer with extensive squamous differentiation require specialized treatment beyond RAI and TSH suppression?
If a patient requires more than 5 mg per day of methimazole long term do you recommend alternative treatment options such as radio-iodine ablation or surgery?
Do you recommend completion thyroidectomy and RAIT in patients found to have unifocal minimally invasive follicular variant of papillary carcinoma on pathology after thyroid lobectomy?
For Graves' disease patients undergoing radioactive iodine ablation, what is the preferred approach to steroid prophylaxis for Graves' orbitopathy?
How do you counsel patients that are positive for both stimulatory and inhibitory autoimmune thyroid markers (TRAb, TSI and TPO Ab) regarding their likelihood of flipping from hyperthyroidism to hypothyroidism?
For patients on desiccated bovine thyroid hormone therapy, how do you approach transitioning to synthetic thyroid hormone derivatives?
In which specific scenarios would you consider transitioning from oral to intravenous thyroid hormone replacement in the outpatient setting?